Skip to search formSkip to main contentSkip to account menu

irinotecan

Known as: (+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate, Irrinotecan, (+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione 
A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Irinotecan, a… 
National Institutes of Health

Related topics

Related topics

35 relations
10 ML irinotecan hydrochloride liposome 4.3 MG/ML Injection [Onivyde]7-ethyl-10-hydroxycamptothecinApoptosisCYP3A7 protein, human

Broader (6)

Antineoplastic AgentsAntineoplastic Agents, PhytogenicCamptothecinEnzyme Inhibitors

Narrower (2)

CamptosarNK012 compound

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma…
4010 Background: In a randomized phase II trial of F vs G in 88 MPA patients (pts), we reported that F induces a response rate… 
Review
2009
Review
2009
10 years of NICE: still growing and still controversial.
Highly Cited
2006
Highly Cited
2006
Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer.
PURPOSE Trials combining irinotecan/docetaxel and irinotecan/gemcitabine in second-line treatment of non-small-cell lung cancer… 
Highly Cited
2004
Highly Cited
2004
Combined Irinotecan and Oxaliplatin in Patients with Advanced Pre-Treated Pancreatic Cancer
Objectives: This study evaluated the clinical activity and toxicity of combination chemotherapy with irinotecan and oxaliplatin… 
Highly Cited
2004
Highly Cited
2004
Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803)
3500 Background: Irinotecan prolongs survival in second line 5FU-refractory metastatic colorectal cancer (MCRC). First line… 
Highly Cited
2003
Highly Cited
2003
Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer.
PURPOSE To identify the maximum-tolerated dose and dose-limiting toxicity (DLT) of weekly irinotecan combined with cisplatin and… 
Review
2003
Review
2003
Clinical and cellular pharmacology in relation to solid tumours of childhood.
Highly Cited
2002
Highly Cited
2002
Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors
Only 20–30% of patients with refractory or recurrent germ cell tumors (GCT) are cured by salvage chemotherapy. Irinotecan, a new… 
Review
2001
Review
2001
The evolution of fluoropyrimidine therapy: from intravenous to oral.
Chemotherapy for advanced colorectal cancer is based on i.v. 5-fluorouracil (5-FU). Numerous attempts have been made to increase… 
Highly Cited
1999
Highly Cited
1999
Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.
PURPOSE To evaluate the efficacy and tolerance of combined irinotecan and oxaliplatin in patients with advanced colorectal cancer… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)